Related Experiment Video
Updated: Dec 14, 2025
A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia
Pragnya Das1, Suchismita Acharya2,3, Dilip Shah1
1Department of Pediatrics, Division of Neonatology, Drexel University, Philadelphia, Pennsylvania, United States.
Insights
A novel compound, AVR-25, shows promise in partially reversing lung damage in a mouse model of bronchopulmonary dysplasia (BPD). This immune modulator may offer a future therapeutic option for infants at high risk of BPD.
Area of Science:
- Neonatal Medicine
- Pulmonary Biology
- Experimental Therapeutics
Background:
- Infants born extremely preterm face a high risk of bronchopulmonary dysplasia (BPD), a severe lung disease.
- BPD is characterized by abnormal lung development, inflammation, and vascular issues, leading to significant healthcare burdens.
- Current treatments for BPD are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of AVR-25, a novel immune modulator, in a mouse model of hyperoxia-induced bronchopulmonary dysplasia.
- To determine if AVR-25 can ameliorate the key pathological features of BPD in a preclinical setting.
Main Methods:
- A hyperoxia-induced mouse model was used to mimic human BPD.
- Mice were treated with the experimental compound AVR-25.
- Pulmonary phenotypes were assessed to evaluate the compound's effects.
Main Results:
- AVR-25 treatment partially restored the pulmonary phenotype in the BPD mouse model.
- The compound demonstrated the ability to counteract some of the lung abnormalities associated with BPD.
Conclusions:
- AVR-25 exhibits therapeutic potential for managing bronchopulmonary dysplasia.
- Further investigation is warranted to explore AVR-25 as a treatment for human BPD.
Abstract:
Infants born extremely preterm are at a high risk of developing bronchopulmonary dysplasia (BPD) which is characterized by large, simplified alveoli, increased inflammation, disrupted and dysregulated vasculogenesis, decreased cell proliferation, and increased cell death in the lungs. Due to lack of specific drug treatments to combat this condition, BPD and its long-term complications have taken a significant toll of healthcare resources. AVR-25, a novel immune modulator experimental compound, was able to partially recover the pulmonary phenotype in the hyperoxia-induced experimental mouse model of BPD. We anticipate that AVR-25 will have therapeutic potential for managing human BPD.
